OncoMatch/Clinical Trials/NCT06713837
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Is NCT06713837 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including High intensity therapies and Low intensity therapies for acute myeloid leukemia.
Treatment: High intensity therapies · Low intensity therapies — This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANCER-01-03, Project ID 101104421)
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Disease stage
Required: Stage RELAPSED, REFRACTORY (European leukemia Network (ELN) 2022)
1st or 2nd relapse or refractory according to European leukemia Network (ELN) 2022
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: investigational agent
Participation in another clinical trial with any investigational agents within 14 days or 5 drug half-lives (whatever comes first) prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify